SCM
TVTX icon

Sigma Capital Management’s Travere Therapeutics TVTX Stock Holding History

Sigma Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-305,000
Closed -$6.49M – 103
2014
Q1 		$6.49M Buy
+305,000
New +$4.69M 0.33% 75

Other funds holding TVTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sigma Capital Management's TVTX Position: Q2 2014 in Review

Sigma Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2014, closing a stake of 305,000 shares — an estimated $6.49M sold.

Sigma Capital Management first reported a position in TVTX in Q1 2014 and held it in 1 quarter. The position peaked at $6.49M in Q1 2014. 59 funds tracked by Wall St. Rank hold TVTX as of Q2 2014.

  • Sigma Capital Management reported no remaining Travere Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Sigma Capital Management sold 305,000 Travere Therapeutics shares in Q2 2014, an estimated $6.49M.
  • Sigma Capital Management first reported a position in Travere Therapeutics in Q1 2014 and held it in 1 quarter.
  • Sigma Capital Management's Travere Therapeutics position peaked at $6.49M in Q1 2014.
  • 59 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2014.

Based on Sigma Capital Management's 13F filing for Q2 2014.